Drug Profile
Research programme: therapeutic agents - AEterna Zentaris/Medical University of South Carolina
Latest Information Update: 28 Apr 2019
Price :
$50
*
At a glance
- Originator AEterna Zentaris Inc; Medical University of South Carolina
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Endocrine disorders; Neurological disorders
Most Recent Events
- 28 Apr 2019 No recent reports of development identified for research development in Cancer in Canada
- 28 Apr 2019 No recent reports of development identified for research development in Endocrine-disorders in Canada
- 28 Apr 2019 No recent reports of development identified for research development in Neurological-disorders in Canada